(R)-melphalan
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- (R)-melphalan
- Molecular weight
- 305.21
- Structure (SMILES)
- N[C@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
- (r)-melphalan
- cb 3026
- CB-3026
- d melphalan
- d phenylalanine mustard
- d sarcolysine
- D-MELPHALAN
- D-PHENYLALANINE MUSTARD
- D-SARCOLYSINE
- medphalan
- MEDPHALAN
- MEDPHALAN [IARC]
- medphalan iarc
- melphalan d
- melphalan d form mi
- MELPHALAN D-FORM [MI]
- MELPHALAN, D-
- nsc 35051
- NSC-35051
- r melphalan
- sarcolysine d
- Sarcolysine, D-
- CAS registry numbers
- 13045-94-8
- ChEMBL ID
- CHEMBL250892
- InChIKey
- SGDBTWWWUNNDEQ-GFCCVEGCSA-N
- FDA ingredient codes (UNII)
- 94H892992X
- 20189
- 6918991
- First in class
- No
- Orphan designation
- No
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- Multiple Myeloma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
Open Targets indications
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 3
- NCT00734877
- NCT02063022
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 2
- Polar surface area
- 66.56
- Calculated partition coefficient (ALogP)
- 1.93
- Calculated partition coefficient (XLogP)
- -0.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 19
- Molecular formula
- C13H18Cl2N2O2
- Monoisotopic mass
- 304.0745332
- Natural product
- Yes
- Recorded assays
- 83
- Active assays
- 6
- Confirmatory
- Other
Oral bioavailability
- Median
- 71
- Mean
- 71
- Minimum
- 71
- Maximum
- 71
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (187)
- [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine
- A Bioavailability Study of GS1-144 Tablets in Healthy Postmenopausal Women
- A Bioavailability Study of Two Different PEG-rhGH Preparations.
- A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa
- A Bioequivalence Study of Two Different PEG-rhGH Preparations.
- A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1502
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
- A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
- A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease
- A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
- A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis
- A PK and Salvage Study for Children With HIV-infection
- A Prospective Cohort of Children With HIV Infection
- A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
- A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
- A Study to Evaluate Chronic Hepatitis C Infection
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
- A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
In development for (2)
- Ewing sarcoma Phase 3
- Plasma cell myeloma Phase 3